187 related articles for article (PubMed ID: 21326159)
1. Acquired amegakaryocytic thrombocytopenia: potential role of thrombopoietin receptor agonists.
Lown R; Rhodes E; Bosworth J; Shannon MS; Stasi R
Clin Adv Hematol Oncol; 2010 Nov; 8(11):809-12. PubMed ID: 21326159
[No Abstract] [Full Text] [Related]
2. Effectiveness of thrombopoietin-receptor agonists in the treatment of refractory immune thrombocytopenia associated to systemic lupus erythematosus.
Magnano L; Enríquez H; Esteve J; Cervera R; Espinosa G
J Rheumatol; 2014 Sep; 41(9):1895-6. PubMed ID: 25179983
[No Abstract] [Full Text] [Related]
3. Thrombopoietin-receptor agonists for immune thrombocytopenia.
Jansen AJ; Swart RM; te Boekhorst PA
N Engl J Med; 2011 Dec; 365(23):2240-1. PubMed ID: 22150056
[No Abstract] [Full Text] [Related]
4. Sequential treatment with thrombopoietin-receptor agonists (TPO-RAs) in immune thrombocytopenia (ITP): experience in our center.
González KJ; Zuluaga SO; DaRos CV; Rodríguez PP; Martí AC
Ann Hematol; 2017 Mar; 96(3):507-508. PubMed ID: 27975127
[No Abstract] [Full Text] [Related]
5. Thrombopoietin receptor agonists in immune thrombocytopenia of less than 6 months duration.
Arumugaswamy A; He S; Quach H; Brotchie J; Grigg A
Intern Med J; 2014 May; 44(5):519-21. PubMed ID: 24816314
[No Abstract] [Full Text] [Related]
6. Thrombopoietin-receptor agonists for primary immune thrombocytopenia.
Imbach P; Crowther M
N Engl J Med; 2011 Aug; 365(8):734-41. PubMed ID: 21864167
[No Abstract] [Full Text] [Related]
7. [Development of thrombopoietin receptor agonists].
Miyakawa Y
Rinsho Ketsueki; 2009 Oct; 50(10):1434-43. PubMed ID: 19915352
[No Abstract] [Full Text] [Related]
8. Absence of bi-directional cross-resistance of thrombopoietin receptor agonists in chronic refractory immune thrombocytopenia: possible role of MPL polymorphisms.
Polverelli N; Palandri F; Iacobucci I; Catani L; Martinelli G; Vianelli N
Br J Haematol; 2013 Apr; 161(1):142-4. PubMed ID: 23278214
[No Abstract] [Full Text] [Related]
9. [Management of refractory ITP with thrombopoietin receptor agonists].
Tomiyama Y
Rinsho Ketsueki; 2011 Aug; 52(8):627-32. PubMed ID: 21897068
[No Abstract] [Full Text] [Related]
10. Venous thromboembolism and coagulation activity in patients with immune thrombocytopenia treated with thrombopoietin receptor agonists.
Ghanima W; Lee SY; Barsam S; Miller A; Sandset PM; Bussel JB
Br J Haematol; 2012 Sep; 158(6):811-4. PubMed ID: 22816787
[No Abstract] [Full Text] [Related]
11. What is publication? The case of eltrombopag.
Benham L; Guo L; Turner R
Lancet; 2011 Jan; 377(9763):360-1. PubMed ID: 21277427
[No Abstract] [Full Text] [Related]
12. Thrombopoietin levels in patients with disorders of platelet production: diagnostic potential and utility in predicting response to TPO receptor agonists.
Makar RS; Zhukov OS; Sahud MA; Kuter DJ
Am J Hematol; 2013 Dec; 88(12):1041-4. PubMed ID: 23913253
[TBL] [Abstract][Full Text] [Related]
13. Thrombopoietin receptor agonists as an emergency treatment for severe newly diagnosed immune thrombocytopenia in children.
Nolla M; Aladjidi N; Leblanc T; Fernandes H; Ducassou S; Fahd M; Barlogis V; Michel M; Blouin P; Jeziorski E; Benadiba J; Pondarre C; Leverger G; Pasquet M
Blood; 2021 Jan; 137(1):138-141. PubMed ID: 33410895
[No Abstract] [Full Text] [Related]
14. Clinical outcomes in eight patients with immune thrombocytopenia each treated with the three approved thrombopoietin receptor agonists.
Lee EJ; Seshadri M; Bussel JB
Am J Hematol; 2021 Oct; 96(10):E373-E376. PubMed ID: 34152624
[No Abstract] [Full Text] [Related]
15. Safety and efficacy of romiplostim in patients with eltrombopag-resistant or -intolerant immune thrombocytopenia.
Tsukamoto S; Nakaseko C; Takeuchi M; Kumagai K; Komatsu T; Tanaka H; Hara S; Koizumi M; Imai H; Yokota A; Takeuchi M; Inokuchi K; Matsuura Y; Aotsuka N; Wakita H
Br J Haematol; 2013 Oct; 163(2):286-9. PubMed ID: 23862773
[No Abstract] [Full Text] [Related]
16. New therapy options for chronic immune thrombocytopenic purpura: a breath of fresh air. Introduction.
Francesco R
Eur J Haematol Suppl; 2009 Mar; (71):1-2. PubMed ID: 19200300
[No Abstract] [Full Text] [Related]
17. Treatment of acquired amegakaryocytic thrombocytopenic purpura with romiplostim.
Shigekiyo T; Sekimoto E; Shibata H; Ozaki S; Fujinaga H; Hirose T
Platelets; 2015; 26(5):504-6. PubMed ID: 24832714
[No Abstract] [Full Text] [Related]
18. Effect of thrombopoietin-receptor agonists on a proliferation-inducing ligand (APRIL) plasma levels in patients with immune thrombocytopaenia.
Álvarez Román MT; Fernández Bello I; Arias-Salgado EG; de Paz R; Jiménez Yuste V; Martín Salces M; Butta NV
Br J Clin Pharmacol; 2014 Sep; 78(3):674-6. PubMed ID: 24602175
[No Abstract] [Full Text] [Related]
19. Thrombopoietin receptor activation, thrombopoietin mimetic drugs, and hereditary thrombocytosis: remarks on bone marrow fibrosis.
Teofili L; Giona F; Martini M; Torti L; Cenci T; Foà R; Leone G; Larocca LM
J Clin Oncol; 2010 Jul; 28(19):e317-8. PubMed ID: 20516451
[No Abstract] [Full Text] [Related]
20. Current status of thrombopoietic agents.
Rhodes E; Stasi R
Expert Rev Hematol; 2010 Apr; 3(2):217-25. PubMed ID: 21083464
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
